Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes with standard therapies and even allogenic stem...
Following the extensive use of immunosuppressive drugs in the clinic, immunosuppression-associated side effects have received increasing attention. Epstein-Barr virus (EBV) reactivation and related lymphoproliferative diseases (LPD) are the lethal complications observed after allogeneic...
CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, the authors initiated a clinical trial with in-house produced CD19...
Recently, the use of immune checkpoint inhibitors has gained attention in the treatment of both cutaneous squamous cell carcinoma and hematological malignancies. However, many patients with hematological malignancies eventually undergo allo-HCT, raising the concern of potential adverse events ...
Presentation slides and video from the 2020 Advances in Cancer Immunotherapy TM - Charleston, SC, held on February 1, 2020 are available here. Program Organizers David M. Neskey, MD – MUSC Hollings Cancer Center Chrystal M. Paulos, PhD – Medical University of South Carolina ...
19 attachments
Presentation slides and video from the 2020 Advances in Cancer Immunotherapy TM – Charlotte, NC, held on January 23, 2020 are available here. Program Organizers Asim Amin, MD, PhD – Levine Cancer Institute Nilanjan Ghosh, MD, PhD – Levine Cancer Institute, Atrium Health Marina...
20 attachments
Hepatitis B virus (HBV) reactivation is commonly seen in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Little is known about the risk of HBV reactivation after chimeric antigen receptor T-cell (CAR T) immunotherapy for the treatment of refractory/relapsed...
Despite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse within 7 years and the disease remains incurable. Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current ATCT protocols...
Diffuse large B-cell lymphoma (DLBCL) harbors somatic hypermutation (SHM) in the immunoglobulin heavy chain and light chain variable region genes, IGHV and IGK/LV. Recent studies have revealed that IGV SHM creates neoantigens that activate T-cell responses against B-cell lymphoma. The authors...
Presentation slides and video from the 2019 Advances in Cancer Immunotherapy TM - San Diego, CA, held on December 12, 2019 are available here. Program Organizers Christopher Coyne, MD, MPH – University of California San Diego Sandip P. Patel, MD – University of California San...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us